Nebivolol: Comparison of the effects of dl-nebivolol, d-nebivolol, l-nebivolol, atenolol, and placebo on exercise-induced increases in heart rate and systolic blood pressure

Cardiovascular Drugs and Therapy

Volumn 12, Issue 4, 1998, Pages 339-344

  Van Nueten, L ^a   De Cree J ^b  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b Jan Palfijn Hospital   (Belgium)

Author keywords

Atenolol; Beta blockade; d nebivolol; dl nebivolol; Endothelium; l nebivolol; Nitric oxide

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NEBIVOLOL; NITRIC OXIDE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; HEART RATE; HUMAN; HUMAN EXPERIMENT; ISOMER; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TIME; TREADMILL EXERCISE;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ATENOLOL; BENZOPYRANS; BLOOD PRESSURE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ETHANOLAMINES; EXERCISE; HEART RATE; HUMANS; MALE; PLACEBOS;

EID: 0031786783     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007760515117     Document Type: Article

References (20)

1. Van de Water A, Janssens W, Van Nueten J, et al. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective β1-adrenergic antagonist. J Cardiovasc Pharmacol 1988;11:552-563.
2. Pauwels PJ, Gommeren W, Van Lommen G, Janssen PAJ, Leysen JE. The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various β1-adrenergic blockers. Mol Pharmacol 1988; 34:843-851.
3. Janssens WJ, Van de Water A, Xhonneux R, Reneman RS, Van Nueten JM, Janssen PAJ. Nebivolol is devoid of intrinsic sympathomimetic activity. Eur J Pharmacol 1989;159: 89-95.
4. Van de Water A, Xhonneux R, Reneman RS, Janssen PAJ. Cardiovascular effects of dl-nebivolol and its enantiomers - a comparison with those of atenolol. Eur J Pharmacol 1988;156:95-103.
5. Van Bortel LMAB, De Hoon JNJM, Kool MJF, et al. Pharmacological properties of nebivolol in man. Eur J. Clin Pharmacol 1997;51:379-384.
6. Gao Y, Nagao T, Bond RA, Janssens WJ, Vanhoutte PM. Nebivolol induces endothelium-dependent relaxations of canine coronary arteries. J Cardiovasc Pharmacol 1991;17: 964-969.
7. Cockroft JR, Chowienczyk PJ, Brett SA, et al. Nebivolol vasodilates human forearm vasculature: Evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995;274:1067-1071.
8. Bowman AJ, Chen CPL-H, Ford GA. Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmacol 1994; 38:199-204.
9. Van Rooy P, Van Nueten L, De Crée J. Nebivolol blood pressure reduction in relation to beta-blockade in healthy volunteers. Drug Invest 1991;3(Suppl. 1):174-175.
10. Van Peer A, Snoeck E, Woestenborghs R, et al. Clinical pharmacokinetics of nebivolol: A review: Drug Invest 1991;3 (Suppl. 1):25-30.
11. Van Nueten L, Dupont AG, Vertommen C, et al. A dose-response trial of nebivolol in essential hypertension. J Hum Hypertens 1997;11:139-144.
12. Scott AK, Rigby JW, Webster J, et al. Atenolol and metoprolol once daily in hypertension. Br Med J 1982;284: 1514-1516.
13. Cruickshank JM, Prichard BNC. Beta-Blockers in Clinical Practice. Edinburgh: Churchill Livingstone, 1987;19,253, 284-297.
14. Eskildsen P, Goztzsche H, Hansen AT. Measuring of the intra-arterial blood pressure during exercise. Acta Med Scand 1950;Suppl. 239:245-250
15. Aoki K, Kato S, Mochizuki A, et al. Abnormal response of blood pressure to Master's two-step exercise in patients with essential hypertension. Jpn Circ J 1982;46:261-266.
16. Tulio S, Eglé S, Greily B. Blood pressure response to exercise of obese and lean hypertensive and normotensive male adolescents. J Hum Hypertens 1995;9:953-958.
17. Ketelhut RG, Ketelhut K, Messerli FM, Bodtke G. Fitness in the fit: Does physical conditioning affect cardiovascular risk factors in middle-aged marathon runners? Eur Heart J 1996;17:199-203.
18. Tanaka H, Bassett DR, Turner MJ. Exaggerated blood pressure response to maximal exercise in endurance-trained individuals. Am J Hypertens 1996;9:1099-1103.
19. Duncan DK. T-tests and intervals for comparisons suggested by the data. Biometrics 1975;31:339-359.
20. Janssen PAJ. Nebivolol: A new form of cardiovascular therapy? Drug Invest 1991;3(Supp. 1):1-2.